873302-39-7

Basic information

• Product Name: N-(5-BROMO-PYRIDIN-3-YL)-2,2-DIMETHYL-PROPIONAMIDE
• Synonyms: N-(5-BROMO-PYRIDIN-3-YL)-2,2-DIMETHYL-PROPIONAMIDE;5-BROMO-3-N-PIVALOYL-AMINOPYRIDINE;N-(5-bromopyridin-3-yl)pivalamide
• CAS NO: 873302-39-7
• Molecular Formula: C10H13BrN2O
• Molecular Weight: 257.13
• Mol File: 873302-39-7.mol
• Article Data: 33

Chemical Properties

• Boiling Point: 365.7°C at 760 mmHg
• Flash Point: 175°C
• Appearance: /
• Density: 1.416g/cm³
• Vapor Pressure: 1.54E-05mmHg at 25°C
• Refractive Index: 1.577
• CAS DataBase Reference: N-(5-BROMO-PYRIDIN-3-YL)-2,2-DIMETHYL-PROPIONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-BROMO-PYRIDIN-3-YL)-2,2-DIMETHYL-PROPIONAMIDE(873302-39-7)
• EPA Substance Registry System: N-(5-BROMO-PYRIDIN-3-YL)-2,2-DIMETHYL-PROPIONAMIDE(873302-39-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 873302-39-7(Hazardous Substances Data)

Usage

General Description

N-(5-Bromo-pyridin-3-yl)-2,2-dimethyl-propionamide is a chemical compound with the molecular formula C11H14BrN3O. It is a pyridine derivative and is classified as a propionamide. N-(5-BROMO-PYRIDIN-3-YL)-2,2-DIMETHYL-PROPIONAMIDE is often used in medicinal chemistry and pharmaceutical research as a building block for the synthesis of new potential drug candidates. It has the potential to exhibit biological activity and may be involved in the development of new drugs for various therapeutic applications. Due to its unique chemical structure, N-(5-Bromo-pyridin-3-yl)-2,2-dimethyl-propionamide is of interest to researchers in the fields of organic chemistry and drug discovery.

InChI:InChI=1/C10H13BrN2O/c1-10(2,3)9(14)13-8-4-7(11)5-12-6-8/h4-6H,1-3H3,(H,13,14)

Upstream product

• 13535-01-8 3-amino-5-bromopyridine 
• 3282-30-2 pivaloyl chloride 

Relevant articles and documents

FUSED RING COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

Provides a compound as shown in formula Ia or IB, a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a polymorph thereof, a metabolite thereof, a stereoisomer thereof, an tautomer thereof, or a prodrug thereof. The compound as a Wnt inhibitor and mesenchymal stem cell inducer, sox9, type I collagen, X. collagen, osteogenetic transcription gene and alkaline phosphatase one or more have a good inducing effect, which can then be used to prepare drugs for the treatment and / or improvement of related diseases and disorders.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF

6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.